For Immediate Release
Chicago, IL – November 13, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Coca-Cola Company (
KO Quick Quote KO - Free Report) , Merck & Co., Inc. ( MRK Quick Quote MRK - Free Report) , Honeywell International Inc. ( HON Quick Quote HON - Free Report) , 3M Company ( MMM Quick Quote MMM - Free Report) and General Electric Company ( GE Quick Quote GE - Free Report) . Here are highlights from Thursday’s Analyst Blog: Top Stock Reports for Coca-Cola, Merck and Honeywell
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola Company, Merck and Honeywell International. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>> Coca-Cola shares have underperformed the Zacks Soft Drinks Beverages industry in the year to date period (-4.1% vs. -1.3%). The Zacks analyst believes that it is poised to gain from the streamlining of portfolios and accelerating investments to expand digital presence due to a shift in consumer preference.
However, continued pressures in the away-from-home channel, which account for nearly half of its revenues, hurt revenue growth. It also lost global value share in NARTD beverages on negative channel mix.
Meanwhile, gains from aggressive cost management aided the bottom line in the third quarter. Moreover, revenues surpassed the Zacks Consensus Estimate. Although the earnings and sales declined on a year over year basis, the company’s third-quarter revenues and volume reflected improved trends from the second quarter.
) read the full research report on Coca-Cola here >>>
Merck have lost -5.8% over the past year against the Zacks Large Cap Pharmaceuticals industry’s rise of +8.3%. The Zacks analyst believes that generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line.
Sales of some key products like Gardasil 9 vaccine are being hurt due to COVID-19-related business disruption. Meanwhile, Merck beat Q3 estimates for both earnings and sales. Merck drugs like Keytruda, Lynparza and Bridion have been driving sales. Keytruda sales are gaining from continued uptake in lung cancer and increasing usage in other cancer indications.
Animal health and vaccine products remain core growth drivers. The potential separation into two companies makes strategic sense as the remaining Merck should be able to achieve higher profits than the combined company.
) read the full research report on Merck here >>> Honeywell’s shares have gained +61.9% over the past six months against the Zacks Diversified Operations industry’s rise of +44.9%. The Zacks analyst believes that strength in defense and space businesses as well as solid demand for warehouse automation products are likely to boost Honeywell’s revenues in the quarters ahead.
Solid demand for personal protective equipment, along with a strong backlog conversion rate, will act as tailwinds. Increased commercial and operational excellence initiatives are likely to improve its near-term profitability. It is committed to rewarding shareholders handsomely.
However, the company believes that the coronavirus outbreak-led market downturn and weak commercial aerospace will adversely impact its near-term results. Given its extensive geographic presence, its business is subject to political, economic and geopolitical issues. Rise in debt levels can increase its financial obligations.
) read the full research report on Honeywell here >>>
Other noteworthy reports we are featuring today include 3M Company and General Electric.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that have beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.